Skip to content
Annika Bansal – Lifestyle
Author:
Racura Oncology Limited
Racura Oncology Presents Bisantrene MYC Data at Frontiers in Cancer Science 2026 Conference
November 12, 2026
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
October 12, 2026
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
June 25, 2026